Literature DB >> 10430602

p53 and cancer therapy: a double-edged sword.

G McGill1, D E Fisher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10430602      PMCID： PMC408427          DOI： 10.1172/JCI7861

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  20 in total

1.  Induction of apoptosis in fibroblasts by c-myc protein.

Authors:  G I Evan; A H Wyllie; C S Gilbert; T D Littlewood; H Land; M Brooks; C M Waters; L Z Penn; D C Hancock
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

2.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

Review 3.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

4.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

Authors:  T Miyashita; J C Reed
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

5.  p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes.

Authors:  C Caelles; A Helmberg; M Karin
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

Review 6.  Apoptosis in cancer therapy: crossing the threshold.

Authors:  D E Fisher
Journal:  Cell       Date:  1994-08-26       Impact factor: 41.582

7.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

Authors:  F Bunz; P M Hwang; C Torrance; T Waldman; Y Zhang; L Dillehay; J Williams; C Lengauer; K W Kinzler; B Vogelstein
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

8.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

9.  Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.

Authors:  A J Wagner; J M Kokontis; N Hay
Journal:  Genes Dev       Date:  1994-12-01       Impact factor: 11.361

10.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728
View more
  9 in total

1.  Zeranol down-regulates p53 expression in primary cultured human breast cancer epithelial cells through epigenetic modification.

Authors:  Weiping Ye; Pingping Xu; Robert Jen; Eric Feng; Saiyi Zhong; Hong Li; Shu-Hong Lin; Jie-Yu Liu; Young C Lin
Journal:  Int J Mol Sci       Date:  2011-02-25       Impact factor: 5.923

2.  Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Authors:  Philippe Bertheau; Elisabeth Turpin; David S Rickman; Marc Espié; Aurélien de Reyniès; Jean-Paul Feugeas; Louis-François Plassa; Hany Soliman; Mariana Varna; Anne de Roquancourt; Jacqueline Lehmann-Che; Yves Beuzard; Michel Marty; Jean-Louis Misset; Anne Janin; Hugues de Thé
Journal:  PLoS Med       Date:  2007-03       Impact factor: 11.069

3.  Genetic Stabilization by p53 Involves Growth Regulatory and Repair Pathways.

Authors:  Lisa Wiesmüller
Journal:  J Biomed Biotechnol       Date:  2001

4.  Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2.

Authors:  A Fedier; U B Ruefenacht; V A Schwarz; U Haller; D Fink
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

5.  Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.

Authors:  Catia Giovannini; Michele Baglioni; Marco Baron Toaldo; Cristiano Ventrucci; Stefania D'Adamo; Mario Cipone; Pasquale Chieco; Laura Gramantieri; Luigi Bolondi
Journal:  Oncotarget       Date:  2013-10

6.  Magnetite nanoparticles inhibit tumor growth and upregulate the expression of p53/p16 in Ehrlich solid carcinoma bearing mice.

Authors:  Heba Bassiony; Salwa Sabet; Taher A Salah El-Din; Mona M Mohamed; Akmal A El-Ghor
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

7.  DRAM1 increases the secretion of PKM2-enriched EVs from hepatocytes to promote macrophage activation and disease progression in ALD.

Authors:  Jie Tan; Jie Zhang; Mengke Wang; Yifen Wang; Mengzhen Dong; Xuefeng Ma; Baokai Sun; Shousheng Liu; Zhenzhen Zhao; Lizhen Chen; Wenwen Jin; Kai Liu; Yongning Xin; Likun Zhuang
Journal:  Mol Ther Nucleic Acids       Date:  2021-12-11       Impact factor: 8.886

8.  Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51.

Authors:  Alice Turdo; Miriam Gaggianesi; Simone Di Franco; Veronica Veschi; Caterina D'Accardo; Gaetana Porcelli; Melania Lo Iacono; Irene Pillitteri; Francesco Verona; Gabriella Militello; Alessio Zippo; Vittoria Poli; Luca Fagnocchi; Sven Beyes; Stefania Stella; Rossano Lattanzio; Naida Faldetta; Vincenzo L Lentini; Rossana Porcasi; Giuseppe Pistone; Maria Rita Bongiorno; Giorgio Stassi; Ruggero De Maria; Matilde Todaro
Journal:  Oncogene       Date:  2022-02-25       Impact factor: 9.867

Review 9.  NRF2 and p53: Januses in cancer?

Authors:  Barak Rotblat; Gerry Melino; Richard A Knight
Journal:  Oncotarget       Date:  2012-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.